|In vivo activation of the p53 pathway by small-molecule antagonists of MDM2|
LT Vassilev, BT Vu, B Graves, D Carvajal, F Podlaski, Z Filipovic, N Kong, ...
Science 303 (5659), 844-848, 2004
|Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell–mediated B-cell …|
E Mössner, P Brünker, S Moser, U Püntener, C Schmidt, S Herter, R Grau, ...
Blood 115 (22), 4393-4402, 2010
|Angiopoietin-2 differentially regulates angiogenesis through TIE2 and integrin signaling|
M Felcht, R Luck, A Schering, P Seidel, K Srivastava, J Hu, A Bartol, ...
The Journal of clinical investigation 122 (6), 1991-2005, 2012
|Chalcone derivatives antagonize interactions between the human oncoprotein MDM2 and p53|
R Stoll, C Renner, S Hansen, S Palme, C Klein, A Belling, W Zeslawski, ...
Biochemistry 40 (2), 336-344, 2001
|p53 contains large unstructured regions in its native state|
S Bell, C Klein, L Müller, S Hansen, J Buchner
Journal of molecular biology 322 (5), 917-927, 2002
|Immunoglobulin domain crossover as a generic approach for the production of bispecific IgG antibodies|
W Schaefer, JT Regula, M Bähner, J Schanzer, R Croasdale, H Dürr, ...
Proceedings of the National academy of Sciences 108 (27), 11187-11192, 2011
|The N-terminal domain of p53 is natively unfolded|
R Dawson, L Müller, A Dehner, C Klein, H Kessler, J Buchner
Journal of molecular biology 332 (5), 1131-1141, 2003
|WT p53, but not tumor-derived mutants, bind to Bcl2 via the DNA binding domain and induce mitochondrial permeabilization|
Y Tomita, N Marchenko, S Erster, A Nemajerova, A Dehner, C Klein, ...
Journal of Biological Chemistry 281 (13), 8600-8606, 2006
|Preclinical activity of the type II CD20 antibody GA101 (obinutuzumab) compared with rituximab and ofatumumab in vitro and in xenograft models|
S Herter, F Herting, O Mundigl, I Waldhauer, T Weinzierl, T Fauti, G Muth, ...
Molecular cancer therapeutics 12 (10), 2031-2042, 2013
|Targeting the p53–MDM2 interaction to treat cancer|
C Klein, LT Vassilev
British journal of cancer 91 (8), 1415-1419, 2004
|Epitope characterization and crystal structure of GA101 provide insights into the molecular basis for type I/II distinction of CD20 antibodies|
G Niederfellner, A Lammens, O Mundigl, GJ Georges, W Schaefer, ...
Blood, The Journal of the American Society of Hematology 118 (2), 358-367, 2011
|Glycoengineered CD20 antibody obinutuzumab activates neutrophils and mediates phagocytosis through CD16B more efficiently than rituximab|
J Golay, F Da Roit, L Bologna, C Ferrara, JH Leusen, A Rambaldi, C Klein, ...
Blood 122 (20), 3482-3491, 2013
|A transcriptionally and functionally distinct PD-1+ CD8+ T cell pool with predictive potential in non-small-cell lung cancer treated with PD-1 blockade|
DS Thommen, VH Koelzer, P Herzig, A Roller, M Trefny, S Dimeloe, ...
Nature medicine 24 (7), 994-1004, 2018
|Epitope interactions of monoclonal antibodies targeting CD20 and their relationship to functional properties|
C Klein, A Lammens, W Schäfer, G Georges, M Schwaiger, E Mössner, ...
MAbs 5 (1), 22-33, 2013
|Progression of lung cancer is associated with increased dysfunction of T cells defined by coexpression of multiple inhibitory receptors|
DS Thommen, J Schreiner, P Müller, P Herzig, A Roller, A Belousov, ...
Cancer immunology research 3 (12), 1344-1355, 2015
|Ang-2-VEGF-A CrossMab, a novel bispecific human IgG1 antibody blocking VEGF-A and Ang-2 functions simultaneously, mediates potent antitumor, antiangiogenic, and antimetastatic …|
Y Kienast, C Klein, W Scheuer, R Raemsch, E Lorenzon, D Bernicke, ...
Clinical Cancer Research 19 (24), 6730-6740, 2013
|Progress in overcoming the chain association issue in bispecific heterodimeric IgG antibodies|
C Klein, C Sustmann, M Thomas, K Stubenrauch, R Croasdale, ...
MAbs 4 (6), 653-663, 2012
|A novel carcinoembryonic antigen T-cell bispecific antibody (CEA TCB) for the treatment of solid tumors|
M Bacac, T Fauti, J Sam, S Colombetti, T Weinzierl, D Ouaret, W Bodmer, ...
Clinical Cancer Research 22 (13), 3286-3297, 2016
|Comparison of the in vitro effects of the anti‐CD20 antibodies rituximab and GA101 on chronic lymphocytic leukaemia cells|
M Patz, P Isaeva, N Forcob, B Müller, LP Frenzel, CM Wendtner, C Klein, ...
British journal of haematology 152 (3), 295-306, 2011
|Target expression, generation, preclinical activity, and pharmacokinetics of the BCMA-T cell bispecific antibody EM801 for multiple myeloma treatment|
A Seckinger, JA Delgado, S Moser, L Moreno, B Neuber, A Grab, S Lipp, ...
Cancer cell 31 (3), 396-410, 2017